Graft Polymer (UK) PLC Updated Investor Presentation (7307N)
27 9월 2023 - 3:02PM
UK Regulatory
TIDMGPL
RNS Number : 7307N
Graft Polymer (UK) PLC
27 September 2023
27 September 2023
Graft Polymer (UK) PLC
("Graft Polymer" or the "Company")
Updated Investor Presentation
Graft Polymer, (LSE:GPL) the speciality multi-sector chemicals
company offering modified and alloys polymers and bio-polymer
solutions for refiners, compounders and processors, is pleased to
announce that an updated Investor Presentation is available today
for downloading from the Company's website at
www.graftpolymer.com
ENDS
For further information, visit www.graftpolymer.com , follow on
Twitter @PolymerLtd or contact:
Graft Polymer (UK) Plc
Roby Zomer, Non-Executive Chairman Via Flagstaff
Yifat Steur, CFO and Executive Chairman
Turner Pope Investments Tel:+44 (0) 20 3657 0050
James Pope
Andy Thacker
Flagstaff Strategic and Investor Communications Tel + 44 (0) 207 129 1474
Tim Thompson graftpolymer@flagstaffcomms.com
Mark Edwards
Alison Allfrey
Anna Probert
About Graft Polymer
Graft Polymer is a London Stock Exchange listed company (GPL.L)
with a cutting-edge, research and development (R&D) and
manufacturing facility based in Slovenia which has already
introduced more than 50 products to the market. The core business
of the Group comprises polymer modification and drug delivery
system developments. The Group has developed a proprietary set of
polymer modification technologies which uses recycled raw materials
and a closed loop system to reduce waste. Graft Polymer's
technology can improve existing products and processing
methodologies by enhancing performance, simplifying manufacturing,
reducing material consumption, widening the choice of feedstocks,
and reducing costs.
Graft Polymer has three divisions: polymer modification; IP for
Bio/Pharma applications including a drug delivery system (Graft
Bio) and the Group's food supplement division. A significant
milestone was reached in May 2022 when the Slovenian manufacturing
facility was granted a Hazard Analysis and Critical Control Point
(HACCP) Certificate. The HACCP Certificate allows it to enter the
lucrative Business-to-Consumer market and commercialise its IP for
Bio/Pharma applications, developing active pharmaceutical
ingredients and drug delivery platforms for use in the food
supplement market, thereby introducing a further revenue stream to
its business.
Environment, Social and Governance is at the forefront of the
Group's strategy and the facility in Slovenia has been granted ISO
14001 accreditation in recognition of the environmental management
systems in place to reduce waste. Graft Polymer only uses REACH and
ROHS certificated raw materials instead of toxic raw materials, and
its extensive R&D programme has also developed specialised
recycling polymer additives which increases the strength of
recycled blends and plastic products whilst also reducing plastic
waste by between 40 and 50 per cent.
ENDS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZGZLKVKGFZM
(END) Dow Jones Newswires
September 27, 2023 02:02 ET (06:02 GMT)
Graft Polymer (uk) (LSE:GPL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Graft Polymer (uk) (LSE:GPL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024